Literature DB >> 9811770

An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein.

N Madani1, D Kabat.   

Abstract

The vif gene of human immunodeficiency virus type 1 (HIV-1) encodes a basic Mr 23,000 protein that is necessary for production of infectious virions by nonpermissive cells (human lymphocytes and macrophages) but not by permissive cells such as HeLa-CD4. It had been proposed that permissive cells may contain an unidentified factor that functions like the viral Vif protein. To test this hypothesis, we produced pseudotyped wild-type and vif-deleted HIV gpt virions (which contain the HIV-1 genome with the bacterial mycophenolic acid resistance gene gpt in place of the viral env gene) in permissive cells, and we used them to generate nonpermissive H9 leukemic T cells that express these proviruses. We then fused these H9 cells with permissive HeLa cells that express the HIV-1 envelope glycoprotein gp120-gp41, and we asked whether the heterokaryons would release infectious HIV gpt virions. The results clearly showed that the vif-deleted virions released by the heterokaryons were noninfectious whereas the wild-type virions were highly infectious. This strongly suggests that nonpermissive cells, the natural targets of HIV-1, contain a potent endogenous inhibitor of HIV-1 replication that is overcome by Vif.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811770      PMCID: PMC110608     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes.

Authors:  D H Gabuzda; K Lawrence; E Langhoff; E Terwilliger; T Dorfman; W A Haseltine; J Sodroski
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity.

Authors:  A M Borman; C Quillent; P Charneau; C Dauguet; F Clavel
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

3.  Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity.

Authors:  K A Page; N R Landau; D R Littman
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

4.  Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells.

Authors:  U von Schwedler; J Song; C Aiken; D Trono
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

5.  Transcomplementation of VIF- HIV-1 mutants in CEM cells suggests that VIF affects late steps of the viral life cycle.

Authors:  D Blanc; C Patience; T F Schulz; R Weiss; B Spire
Journal:  Virology       Date:  1993-03       Impact factor: 3.616

6.  Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles.

Authors:  H Sakai; R Shibata; J Sakuragi; S Sakuragi; M Kawamura; A Adachi
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

7.  Context-dependent role of human immunodeficiency virus type 1 auxiliary genes in the establishment of chronic virus producers.

Authors:  F Mustafa; H L Robinson
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

8.  Subcellular localization of the Vif protein of human immunodeficiency virus type 1.

Authors:  J Goncalves; P Jallepalli; D H Gabuzda
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

9.  Conservation of amino-acid sequence motifs in lentivirus Vif proteins.

Authors:  M S Oberste; M A Gonda
Journal:  Virus Genes       Date:  1992-01       Impact factor: 2.332

10.  Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1.

Authors:  D Kabat; S L Kozak; K Wehrly; B Chesebro
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

View more
  92 in total

Review 1.  Human immunodeficiency virus and AIDS: insights from animal lentiviruses.

Authors:  R J Miller; J S Cairns; S Bridges; N Sarver
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells.

Authors:  P D Bieniasz; B R Cullen
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 3.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

4.  Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.

Authors:  P Sova; D J Volsky; L Wang; W Chao
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

5.  Recent Insights into HIV Accessory Proteins.

Authors:  Jenny L. Anderson; Thomas J. Hope
Journal:  Curr Infect Dis Rep       Date:  2003-10       Impact factor: 3.725

6.  A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.

Authors:  Heather L Wiegand; Brian P Doehle; Hal P Bogerd; Bryan R Cullen
Journal:  EMBO J       Date:  2004-05-20       Impact factor: 11.598

7.  HIV-1 Vif promotes the G₁- to S-phase cell-cycle transition.

Authors:  Jiangfang Wang; Emma L Reuschel; Jason M Shackelford; Lauren Jeang; Debra K Shivers; J Alan Diehl; Xiao-Fang Yu; Terri H Finkel
Journal:  Blood       Date:  2010-12-13       Impact factor: 22.113

8.  Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Authors:  Judd F Hultquist; Reuben S Harris
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

9.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child.

Authors:  Louis Alexander; Mary Janette Aquino-DeJesus; Michael Chan; Warren A Andiman
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Core Binding Factor β Protects HIV, Type 1 Accessory Protein Viral Infectivity Factor from MDM2-mediated Degradation.

Authors:  Yusuke Matsui; Keisuke Shindo; Kayoko Nagata; Noriyoshi Yoshinaga; Kotaro Shirakawa; Masayuki Kobayashi; Akifumi Takaori-Kondo
Journal:  J Biol Chem       Date:  2016-10-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.